Based on the results of three data sets named GSE17536, GSE17537, GSE12945, we demonstrated that colon cancer patients with lower expression of GSTM2 had worse overall survival rates (OS), disease-free survival (DFS) and disease specific survival rates (DSS) (Figures 3A–H). This evidence concerns the gene GSTM2 and colonic neoplasm.